B2B buyers sourcing CJC-1295 without DAC / Modified GRF 1-29 should confirm DAC status, sequence reference, molecular weight, salt form, documentation scope, and quote unit before comparing supplier prices. The biggest sourcing risk is that suppliers may use “CJC-1295,” “CJC-1295 without DAC,” and “Modified GRF 1-29” inconsistently in catalog listings and quotations.
A common procurement mistake is asking for “CJC-1295 price” without confirming whether the supplier is quoting the DAC form or the no-DAC / Modified GRF 1-29 form. If DAC status, sequence, CAS reference where applicable, molecular weight, and documentation scope are not clear, the quotation is not ready for serious comparison.
This guide is written for distributors, private label brand owners, OEM project teams, formulation consultants, and procurement buyers evaluating CJC-1295 without DAC / Modified GRF 1-29 in bulk powder, lyophilized vial, or custom fill project formats.
It is a B2B sourcing and specification reference. It does not provide end-user application guidance, biological-effect discussion, clinical recommendations, or outcome claims.
What Should Buyers Confirm First When Sourcing CJC-1295 without DAC / Modified GRF 1-29?
Buyers should first confirm whether the supplier is quoting the no-DAC material and not the DAC form. CJC-1295 with DAC and CJC-1295 without DAC / Modified GRF 1-29 are not interchangeable sourcing terms, so the specification sheet must clearly define the material being quoted.
A sourcing review should clarify:
- Product name used by the supplier.
- Whether DAC is absent or included.
- Whether the supplier describes the item as Modified GRF 1-29.
- Exact amino acid sequence or sequence reference.
- CAS reference where applicable.
- Molecular formula and molecular weight.
- Salt form or counterion where relevant.
- Bulk powder or lyophilized vial format.
- Documentation package.
- Batch number once material is allocated.
The supplier’s product name alone is not enough. The buyer should review the specification sheet, COA, HPLC report, LC-MS report where available, label, and packing information to confirm that all documents refer to the same material definition.
Why Do CJC-1295 without DAC Sourcing Projects Stall?
CJC-1295 without DAC sourcing projects usually stall because buyers and suppliers use similar names for different materials. The project often becomes unclear when DAC status, sequence, molecular weight, quote unit, or documentation scope is finally reviewed.
Common reasons these projects stall include:
- Supplier quotes “CJC-1295” without stating DAC status.
- Buyer assumes CJC-1295 without DAC and Modified GRF 1-29 mean the same material in every supplier catalog.
- Sequence reference is missing from the specification sheet.
- CAS reference is copied from a different form.
- Molecular weight does not match the expected no-DAC sequence reference.
- LC-MS availability is not clarified before quotation.
- USD/vial quote is provided without fill amount.
- MOQ is stated without stock vs. production basis.
- Lead time is presented as one number without QC and documentation scope.
A stronger RFQ should ask the supplier to confirm DAC status, sequence, molecular weight, salt form, documentation, format, MOQ, and quote unit before any price comparison.
How Should Buyers Clarify CJC-1295 with DAC vs. without DAC?
Buyers should treat DAC status as a first-line qualification question. If the supplier cannot clearly state whether the quoted material includes DAC, the quote should not enter final comparison.
| Buyer Question | Why It Matters | Acceptable Supplier Response |
|---|---|---|
| Is this CJC-1295 with DAC or without DAC? | Confirms whether the material definition matches the RFQ | Supplier states DAC status clearly |
| Is this also described as Modified GRF 1-29? | Clarifies naming convention used by the supplier | Supplier explains naming and sequence reference |
| What is the exact sequence reference? | Prevents name-based substitution errors | Supplier provides full sequence or verified specification |
| What molecular weight is used in the COA? | Confirms whether the mass aligns with the quoted material | Supplier provides theoretical and observed mass where available |
| Does the COA match the specification sheet? | Checks document consistency | Same product name, batch, and identity fields align |
| Is LC-MS available? | Supports molecular identity review | Supplier states whether LC-MS is standard, optional, or unavailable |
A supplier that only answers “yes, available” without defining DAC status and sequence is not giving enough information for a B2B sourcing decision.
What Specification Fields Should Every Buyer Review?
Before issuing an RFQ, buyers should review the product name, DAC status, sequence reference, molecular weight, purity method, salt form, storage conditions, and documentation scope. Missing any of these fields weakens quote comparison.
| Specification Field | What Buyers Should Confirm |
|---|---|
| Product name | CJC-1295 without DAC / Modified GRF 1-29 naming consistency |
| DAC status | Confirm no DAC extension is included |
| Sequence reference | Full sequence or supplier-defined standard |
| CAS reference | Confirm with supplier specification; do not assume DAC CAS applies |
| Molecular formula | Must align with supplier specification |
| Molecular weight | Confirm theoretical and observed mass where LC-MS is available |
| Purity | HPLC area% and required threshold |
| Salt form / counterion | Acetate, TFA, or other form where relevant |
| Appearance | White to off-white lyophilized powder or supplier-defined standard |
| Storage condition | Confirm temperature, moisture, and light-protection guidance |
| Shelf life / retest date | Confirm lot-specific or supplier-standard statement |
The specification sheet should be reviewed before price comparison. If the specification does not clearly define DAC status or sequence, the buyer should request clarification before proceeding.
What Documents Should Buyers Request Before Comparing Quotes?
Buyers should request COA, HPLC report, LC-MS report where available, SDS, and specification sheet before comparing CJC-1295 without DAC suppliers. Each document verifies a different part of supplier qualification.
| Document | What It Confirms | When to Request | Why It Matters Here |
|---|---|---|---|
| COA | Batch identity, purity, appearance, test results | Qualification stage | Confirms lot-level data |
| HPLC report | Purity by chromatographic method | With COA | Supports purity figure |
| LC-MS report | Molecular weight and identity support | Before final comparison where available | Helps confirm no-DAC material definition |
| SDS | Handling, storage, and transport information | Before shipment discussion | Supports freight and safety review |
| Specification sheet | Supplier’s product standard | Before quote comparison | Defines DAC status, sequence, and quality basis |
The COA should show batch number, issue date, purity result, test method, appearance, and relevant identity fields. The HPLC report should support the purity figure. LC-MS, where available, helps review whether the observed mass matches the expected no-DAC sequence reference.
Documentation does not guarantee import clearance, registration, sale permission, or approval in any destination market. Buyers remain responsible for destination-market compliance and downstream channel obligations.
For broader documentation review, see WUMO’s research-grade peptide shipment documents checklist.
What Red Flags Suggest a Supplier Is Not Ready for B2B Projects?
The biggest red flags are unclear DAC status, missing sequence reference, no specification sheet, no LC-MS availability explanation, and quotation issued before project scope is defined. These gaps make supplier comparison unreliable.
| Red Flag | Why It Matters | Buyer Action |
|---|---|---|
| Supplier says only “CJC-1295 available” | DAC status is unclear | Request no-DAC confirmation |
| Specification sheet lacks sequence | Product identity is not defined | Request full sequence or verified spec |
| CAS reference appears copied from another form | Possible material mismatch | Ask supplier to explain reference |
| Molecular weight does not align with expected material | Identity review problem | Request LC-MS or clarification |
| COA has no batch number | No batch traceability | Treat as incomplete documentation |
| HPLC purity stated without chromatogram | Purity claim cannot be reviewed | Request HPLC report |
| LC-MS unavailable without explanation | Identity review is incomplete | Ask whether optional test is available |
| USD/vial quote lacks fill amount | Price cannot be normalized | Request fill amount per vial |
| MOQ is stated verbally only | No written batch basis | Request formal MOQ basis |
| Auto-quote issued without specification review | Supplier may not evaluate project fit | Request specification-backed quote |
A low price with unclear DAC status is not a strong quote. It is a high-clarification quote.
Should Buyers Choose Bulk Powder or Lyophilized Vial Format?
The right format depends on the buyer’s project stage and downstream capability. Bulk powder suits buyers that need further processing or repackaging; lyophilized vial format suits projects that need a defined vial-based unit.
| Factor | Bulk Powder | Lyophilized Vial |
|---|---|---|
| Typical buyer | Distributor, formulator, repackager | Private label, OEM, distribution-ready project |
| Quote unit | USD/g or USD/mg | USD/vial or USD/box |
| MOQ basis | Gram quantity or batch size | Vial count, box count, or fill batch |
| Key specification issue | DAC status, sequence, purity, salt form | Fill amount, vial size, label, packaging |
| Lead time | Shorter if stock exists | Longer due to fill-and-finish steps |
| Documentation | COA, HPLC, LC-MS, SDS, specification sheet | Core documents plus fill and packaging details |
| Custom options | Container size, packaging format | Fill amount, vial configuration, label format |
| Shipment planning | Storage and packaging requirements | Storage, vial packaging, box format, freight planning |
A USD/g quote for bulk powder cannot be directly compared with a USD/vial quote for finished vials. Buyers should separate peptide material cost, filling service, packaging, documentation, and shipment scope before choosing a format.
For broader vial project scoping, see WUMO’s lyophilized peptide vial sourcing guide.
What Do MOQ and Lead Time Actually Mean for This Project?
MOQ and lead time depend on format, stock status, documentation scope, and whether the project requires custom filling or private label packaging. Buyers should confirm both in writing before accepting a quotation.
| Scenario | MOQ Basis | Lead Time Factor | Key Confirmation |
|---|---|---|---|
| Bulk powder, in stock | Per gram or available lot | Shorter | Confirm stock quantity and retest date |
| Bulk powder, production required | Minimum batch size | Longer | Confirm production and QC timeline |
| Standard lyophilized vial | Vial count or batch minimum | Moderate to long | Confirm fill schedule and available batch |
| Custom fill, standard label | Batch minimum | Long | Confirm fill amount and vial format |
| Custom fill, private label | Batch minimum plus packaging scope | Longest | Confirm artwork and approval timing |
A single lead time number is rarely enough. Buyers should ask whether the stated timeline includes material availability, production, QC testing, documentation preparation, vial filling, packaging, export preparation, and dispatch.
Freight transit time is separate from production lead time. Buyers should not treat supplier production lead time as delivered lead time.
How Should Buyers Prepare a Stronger RFQ?
A stronger RFQ should define DAC status, sequence reference, format, fill amount, documentation scope, MOQ range, destination, and timeline before the supplier responds. Without these fields, suppliers may quote against their own default product definition.
| RFQ Field | Why It Matters |
|---|---|
| Product name | Clarifies whether buyer requests CJC-1295 without DAC or Modified GRF 1-29 |
| DAC status | Prevents confusion with CJC-1295 with DAC |
| Sequence reference | Confirms product identity |
| CAS reference where applicable | Supports supplier document matching |
| Molecular weight reference | Helps compare COA and LC-MS data |
| Format | Determines MOQ, quote unit, and lead time |
| Fill amount if vials are requested | Required for USD/vial comparison |
| Required documents | Sets expectations for COA, HPLC, LC-MS, SDS, specification sheet |
| Target MOQ range | Filters out mismatched suppliers |
| Destination country or region | Supports SDS, label, and freight planning |
| Project timeline | Helps supplier judge feasibility |
| Quote unit preference | Avoids USD/g vs USD/vial mismatch |
A weak RFQ asks only for product name, quantity, and price. A stronger RFQ gives the supplier enough structure to issue a specification-backed quotation.
What Supplier Qualification Checkpoints Apply?
A qualified supplier should define DAC status, sequence, molecular weight reference, documentation scope, MOQ basis, and lead time before issuing a formal quotation. If a supplier auto-quotes without clarifying these points, the buyer should slow down.
Supplier qualification checkpoints include:
- Supplier confirms CJC-1295 without DAC / Modified GRF 1-29 naming.
- DAC status is clearly stated.
- Sequence reference is provided.
- Specification sheet is available before formal quotation.
- Batch-specific COA is available.
- HPLC chromatogram supports the purity result.
- LC-MS or mass confirmation is available where requested.
- SDS is available at inquiry stage.
- Batch number links to COA and test records.
- Lead time is stated with stock vs. production basis.
- MOQ is confirmed in writing with batch basis explained.
- Supplier reviews buyer specification before quoting.
- Custom fill or private label capability is confirmed if required.
For a broader supplier review framework, see WUMO’s peptide supplier qualification checklist.
What Does WUMO Review Before Issuing a Formal Quotation?
WUMO reviews DAC status, sequence, documentation, MOQ feasibility, quote unit basis, and project fit before issuing a formal quotation. A useful quotation starts with product definition rather than an automatic price.
WUMO may review:
- Whether the request is for CJC-1295 without DAC / Modified GRF 1-29.
- Product name and sequence reference.
- Bulk powder vs. lyophilized vial format.
- Target quantity and quote unit.
- Fill amount if vial format is requested.
- Documentation scope: COA, HPLC, LC-MS, SDS, specification sheet.
- Batch traceability requirements.
- MOQ and lead time expectations.
- Packaging and label scope.
- Destination-market shipment considerations.
- Whether NDA is needed before custom project discussion.
This review helps avoid quoting the wrong material definition, wrong format, wrong unit, or wrong documentation scope.
How Does WUMO Support Qualified CJC-1295 without DAC B2B Sourcing Projects?
WUMO supports qualified B2B buyers with CJC-1295 without DAC / Modified GRF 1-29 sourcing discussion, specification review, documentation review, and project quotation support.
For these projects, WUMO can help buyers clarify:
- Bulk powder or lyophilized vial format.
- CJC-1295 without DAC vs. other naming references.
- Product identity and sequence reference.
- Documentation scope.
- COA, HPLC, LC-MS, SDS, and specification sheet availability.
- MOQ and volume tier discussion.
- Lead time assumptions.
- Quote basis.
- Custom fill feasibility.
- Neutral label or private label discussion.
- Packaging scope.
- Project fit before formal quotation.
Availability may vary by batch, project type, destination requirement, and buyer specification. Buyers are encouraged to state product definition, format, documentation, MOQ, and packaging requirements before quotation so the project can be reviewed properly.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and CJC-1295 without DAC in a sourcing context?
The key sourcing difference is DAC status. Buyers should confirm whether the supplier is quoting the DAC form or the no-DAC / Modified GRF 1-29 form, then verify sequence reference, molecular weight, and documentation before comparing price.
Is CJC-1295 without DAC the same as Modified GRF 1-29?
Many suppliers use CJC-1295 without DAC and Modified GRF 1-29 as related sourcing terms, but buyers should not rely on naming alone. They should confirm exact sequence, DAC status, molecular weight, and supplier specification before accepting a quotation.
What documents should I request before comparing CJC-1295 without DAC suppliers?
Buyers should request specification sheet, batch-specific COA, HPLC report, LC-MS availability, SDS, and storage or handling information before serious quote comparison. These documents help define product identity, purity method, and batch traceability.
Why is DAC status important in supplier qualification?
DAC status changes the material definition and can affect molecular weight, naming, and documentation comparison. A supplier that cannot clearly state DAC status should not be treated as ready for final B2B comparison.
How should I compare USD/g and USD/vial quotes for CJC-1295 without DAC?
Normalize quotes to a peptide-content basis such as USD/mg or USD/g, then separately review fill amount, vial count, documentation, MOQ, packaging, and shipment scope. USD/vial is not comparable without fill amount.
What are the most common red flags in CJC-1295 without DAC quotations?
Common red flags include unclear DAC status, missing sequence reference, copied CAS reference, COA without batch number, purity claim without HPLC support, no LC-MS availability statement, and quote issued without project scope review.
What should a stronger RFQ include?
A stronger RFQ should include product name, DAC status, sequence reference, target quantity, preferred quote unit, required documents, format, fill amount if vials are requested, destination country, project timeline, and packaging requirements.
Does COA and HPLC documentation guarantee import clearance?
No. COA and HPLC documents support sourcing review, but they do not guarantee import clearance, regulatory approval, sale permission, or downstream compliance in any destination market. Buyers remain responsible for destination-market requirements.
Can WUMO discuss custom fill or private label projects for this peptide?
WUMO can discuss custom fill, neutral label, and private label project requirements with qualified B2B buyers. Feasibility depends on project scope, MOQ, documentation requirements, destination considerations, and supplier-side review.
What does WUMO review before issuing a formal quotation?
WUMO reviews DAC status, sequence reference, format, target quantity, quote unit, documentation scope, MOQ feasibility, lead time assumptions, packaging requirements, and destination-market shipment considerations before issuing a formal quotation.
CTA
If you are evaluating CJC-1295 without DAC / Modified GRF 1-29 as a B2B sourcing project, WUMO can review your specification, confirm available documentation, and discuss format options, MOQ, and project fit before issuing a formal quotation.
Qualified B2B buyers are welcome to submit a project inquiry with product definition, preferred format, quantity, quote unit, and documentation requirements.